All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-02-01T12:31:18.000Z

Clinical characteristics and the pattern of progression are important prognostic factors for post-progression survival in multiple myeloma

Feb 1, 2019
Share:

Bookmark this article

Multiple relapses requiring several lines of therapy characterizes multiple myeloma (MM), with the durability of remissions improved over recent years by the development of novel agents such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (MoAbs).1 The International Myeloma Working Group (IMWG) categorizes disease relapse into progressive disease, an increase in measurable monoclonal protein by 25%, and clinical relapse, new end-organ dysfunction.2,3 Rajshekhar Chakraborty from the Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA, and colleagues, conducted a retrospective cohort study which aimed to evaluate survival following clinical progression (CP), with and without extramedullary (EM+/EM-), as a measure of biochemical progression (BP) in patients with MM.4 

All consecutive newly diagnosed MM patients (n = 527) treated at the Cleveland Clinic between 1 January 2008 and 31 December 2015 were analyzed for treatment course and progression pattern, with follow-up for relapse continuing until 28 February 2018. Throughout this time period, induction, maintenance, and subsequent therapies routinely consisted of PIs and IMiDs.

Key findings

All data are shown as BP vs CR/EM- vs CR/EM+, where applicable

  • Patients experiencing first relapse by February 2018 and requiring further therapy, n = 252
  • Median age at first relapse: 64 years (range, 27–87)
  • Median time from diagnosis to first relapse: 24 months (range, 2–84)
  • No significant difference in relapse patterns in patients who received PIs and/or IMiDs vs traditional cytotoxic agents as first-line therapy
  • At time of disease progression, 134 patients (53%) had BP and 118 patients (47%) presented with CP, of which 35% had CP/EM- and 12% had CP/EM+ 
  • High-risk cytogenetics at diagnosis were found in a greater proportion of patients presenting with CP/EM+ compared to CP/EM- or BP: 45% vs 35% vs 22%, P = 0.09, respectively
  • Median time from diagnosis to first relapse was shorter in patients presenting with CP/EM+ compared to CP/EM- or BP, respectively: 13 months vs 25 months vs 25 months, P = 0.003
  • Median follow-up of patients: 27 months vs 23 months vs 32 months
  • Median overall survival: 49.5 months vs 19.2 months vs 10.2 months, P < 0.001
  • Median progression-free survival: 16.7 months vs 6.3 months vs 5.1 months, P < 0.001

In conclusion, this retrospective analysis illustrates that clinical characteristics and the pattern of progression are important prognostic factors in post-progression survival for MM patients. The authors added that these findings highlight the importance of reporting the pattern of progression for relapsed MM patients at entry into clinical trials. To validate the prognostic significance of the pattern of progression, prospective trials are needed.

  1. Kumar S.K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014 May; 28(5): 1122–1128. DOI: 10.1038/leu.2013.313.
  2. Kumar S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug; 17(8): 328–346. DOI: 10.1016/S1470-2045(16)30206-6.
  3. Laubach J. et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016 May; 30(5): 1005–1017. DOI: 10.1038/leu.2015.356.
  4. Chakraborty R. et al. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Am J Hematol. 2019 Jan 21. DOI: 10.1002/ajh.25415. [Epub ahead of print]

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox